SA PRO
Free Account
Trevi Therapeutics, Inc.TRVINASDAQ
LOADING
|||
Switch Symbol:
OverviewChartsNewsFundamentalsEarningsAnalysts

Analyst Sentiment

Analysts lean bullish — 100% recommend buying.

Consensus Rating
Buy
16 analysts·Moderate coverage
100%
Rating Distribution
Strong Buy
16%
Buy
1594%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Earnings & Revenue Estimates

Earnings Surprises

Beat rate:75%(9/12 quarters)
Avg surprise:+12.8%
Beat
Miss
Inline
Estimate
Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Dec 19, 2025Stifel Nicolaus
Trevi Therapeutics price target raised to $18 from $15 at Stifel
Target:$18.00
+47.7%from $12.19
Nov 19, 2025Leerink Partners
Trevi Therapeutics (TRVI) PT Raised to $16 at Leerink Partners
Target:$16.00
+41.5%from $11.31
Nov 14, 2025Morgan Stanley
Trevi Therapeutics price target raised to $19 from $18 at Morgan Stanley
Target:$19.00
+62.7%from $11.68
Nov 14, 2025Oppenheimer
Trevi Therapeutics (TRVI) PT Raised to $24 at Oppenheimer
Target:$24.00
+103.4%from $11.80
Oct 22, 2024H.C. Wainwright
H.C. Wainwright Reiterates Buy Rating on Trevi Therapeutics (TRVI)
Target:$6.00
+79.1%from $3.35
Oct 4, 2024B.Riley Financial
B.Riley Reiterates Buy Rating on Trevi Therapeutics (TRVI)
Target:$6.00
+98.7%from $3.02
Jul 9, 2022Oppenheimer
Trevi Therapeutics (TRVI) Stock: $12 Target And Outperform Rating
Target:$12.00
+203.8%from $3.95

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance